NPS Pharmaceuticals, Inc. (NPSP) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.

The profile contains critical company information including:

- Business description – A detailed description of the company’s operations and business divisions.
- Corporate strategy – Analyst’s summarization of the company’s business strategy.
- SWOT Analysis – A detailed analysis of the company’s strengths, weakness, opportunities and threats.
- Company history – Progression of key events associated with the company.
- Major products and services – A list of major products, services and brands of the company.
- Key competitors – A list of key competitors to the company.
- Key employees – A list of the key executives of the company.
- Executive biographies – A brief summary of the executives’ employment history.
- Key operational heads – A list of personnel heading key departments/functions.
- Important locations and subsidiaries – A list and contact details of key locations and subsidiaries of the company.
- Key manufacturing facilities – A list of key manufacturing facilities of the company.
- Detailed financial ratios for the past five years – The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
- Interim ratios for the last five interim periods – The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.

Highlights

NPS Pharmaceuticals, Inc. (NPS) is a biopharmaceutical company focused on the development of specialty therapeutics for the treatment of rare diseases and disorders. The company’s only marketed product is Gattex (teduglutide) indicated for the treatment of intestinal failure associated with short bowel syndrome.

NPS Pharmaceuticals, Inc. Key Recent Developments

Mar 25, 2014: NPS Pharmaceuticals Expands Executive Leadership Team to Support its U.S. and International Growth and Global Orphan-Drug Leadership
Feb 18, 2014: NPS Pharmaceuticals Reports Fourth Quarter and Full-Year 2013 Financial Results and Financial Outlook for 2014
Jan 08, 2014: NPS Pharmaceuticals Reports Preliminary 2013 Results and 2014 Financial Outlook
Jan 06, 2014: NPS Pharmaceuticals to Present at J.P. Morgan Healthcare Conference
Dec 06, 2013: NPS Pharmaceuticals to Present at Oppenheimer Healthcare Conference

Key benefits of buying this profile include:

You get detailed information about the company and its operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.

Understand and respond to your competitors’ business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.
- The company’s core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.

Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.
- Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.

Scout for potential investments and acquisition targets, with detailed insight into the companies’ strategic, financial and operational performance.
- Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.

Gain key insights into the company for academic or business research.
- Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.

Note: Some sections may be missing if data is unavailable for the company

Table Of Contents

NPS Pharmaceuticals, Inc. (NPSP) - Financial and Strategic SWOT Analysis Review
Table of Contents

Section 1 - About the Company 5
NPS Pharmaceuticals, Inc. - Key Facts 5
NPS Pharmaceuticals, Inc. - Key Employees 6
NPS Pharmaceuticals, Inc. - Key Employee Biographies 7
NPS Pharmaceuticals, Inc. - Major Products and Services 8
NPS Pharmaceuticals, Inc. - Pharmaceutical Pipeline Products Data 9
NPS Pharmaceuticals, Inc., Pipeline Products by Therapy Area 9
NPS Pharmaceuticals, Inc., Pipeline Products by Development Phase 10
NPS Pharmaceuticals, Inc. - History 12
NPS Pharmaceuticals, Inc. - Company Statement 15
NPS Pharmaceuticals, Inc. - Locations And Subsidiaries 16
Head Office 16
Other Locations and Subsidiaries 16
Section 2 - Company Analysis 17
NPS Pharmaceuticals, Inc. - Business Description 17
NPS Pharmaceuticals, Inc. - Corporate Strategy 18
NPS Pharmaceuticals, Inc. - SWOT Analysis 19
SWOT Analysis - Overview 19
NPS Pharmaceuticals, Inc. - Strengths 19
Strength - Strong Intellectual Property Portfolio 19
Strength - Orphan Drug Designations - Gattex and Natpara 19
Strength - Sturdy Research and Development Activities 19
NPS Pharmaceuticals, Inc. - Weaknesses 19
Weakness - Dependence on Third Parties 19
NPS Pharmaceuticals, Inc. - Opportunities 20
Opportunity - Market Potential - SBS, Hyperparathyroidism 20
Opportunity - Strategic Agreements 20
Opportunity - US Osteoporosis Market 20
NPS Pharmaceuticals, Inc. - Threats 20
Threat - Tightening of FDA's Regulatory Oversight 20
Threat - Uncertain RandD Outcomes 20
Threat - Competitive Landscape 21
NPS Pharmaceuticals, Inc. - Key Competitors 22
Section 3 - Company Financial Ratios 23
Financial Ratios - Capital Market Ratios 23
Financial Ratios - Annual Ratios 23
Performance Chart 25
Financial Performance 25
Financial Ratios - Interim Ratios 26
Financial Ratios - Ratio Charts 27
Section 4 - Company's Lifesciences Financial Deals and Alliances 28
NPS Pharmaceuticals, Inc., Pharmaceuticals and Healthcare, Deals By Year, 2008 to YTD 2014 28
NPS Pharmaceuticals, Inc., Pharmaceuticals and Healthcare, Deals By Type, 2008 to YTD 2014 29
NPS Pharmaceuticals, Inc., Recent Deals Summary 30
Section 5 - Company's Recent Developments 31
NPS Pharmaceuticals, Inc., Recent Developments 31
Mar 25, 2014: NPS Pharmaceuticals Expands Executive Leadership Team to Support its U.S. and International Growth and Global Orphan-Drug Leadership 31
Feb 18, 2014: NPS Pharmaceuticals Reports Fourth Quarter and Full-Year 2013 Financial Results and Financial Outlook for 2014 31
Jan 08, 2014: NPS Pharmaceuticals Reports Preliminary 2013 Results and 2014 Financial Outlook 32
Jan 06, 2014: NPS Pharmaceuticals to Present at J.P. Morgan Healthcare Conference 33
Dec 06, 2013: NPS Pharmaceuticals to Present at Oppenheimer Healthcare Conference 33
Dec 05, 2013: NPS Pharmaceuticals to Webcast Investor and Analyst Event 34
Nov 25, 2013: NPS Pharmaceuticals to Present at Deutsche Bank BioFEST Conference 34
Nov 20, 2013: NPS Pharmaceuticals named one of New Jersey's 50 fastest growing companies by NJBIZ 34
Nov 18, 2013: NPS Pharmaceuticals' president and CEO Dr. Francois Nader receives Ernst and Young National Entrepreneur Of The Year 2013 award in the life sciences category 34
Nov 11, 2013: NPS Pharmaceuticals to Present at Jefferies Global Healthcare Conference 35
Section 6 - Appendix 36
Methodology 36
Ratio Definitions 36
About GlobalData 40
Contact Us 40
Disclaimer 40

List of Tables

NPS Pharmaceuticals, Inc., Key Facts 5
NPS Pharmaceuticals, Inc., Key Employees 6
NPS Pharmaceuticals, Inc., Key Employee Biographies 7
NPS Pharmaceuticals, Inc., Major Products and Services 8
NPS Pharmaceuticals, Inc., Number of Pipeline Products by Therapy Area 9
NPS Pharmaceuticals, Inc., Number of Pipeline Products by Development Stage 10
NPS Pharmaceuticals, Inc., Pipeline Products By Therapy Area and Development Phase 11
NPS Pharmaceuticals, Inc., History 12
NPS Pharmaceuticals, Inc., Subsidiaries 16
NPS Pharmaceuticals, Inc., Key Competitors 22
NPS Pharmaceuticals, Inc., Ratios based on current share price 23
NPS Pharmaceuticals, Inc., Annual Ratios 23
NPS Pharmaceuticals, Inc., Interim Ratios 26
NPS Pharmaceuticals, Inc., Pharmaceuticals and Healthcare, Deals By Year, 2008 to YTD 2014 28
NPS Pharmaceuticals, Inc., Pharmaceuticals and Healthcare, Deals By Type, 2008 to YTD 2014 29
NPS Pharmaceuticals, Inc., Recent Deals Summary 30
Currency Codes 36
Capital Market Ratios 36
Equity Ratios 37
Profitability Ratios 37
Cost Ratios 38
Liquidity Ratios 38
Leverage Ratios 39
Efficiency Ratios 39

List of Figures

NPS Pharmaceuticals, Inc., Pipeline Products by Therapy Area 9
NPS Pharmaceuticals, Inc., Pipeline Products by Development Phase 10
NPS Pharmaceuticals, Inc., Performance Chart (2009 - 2013) 25
NPS Pharmaceuticals, Inc., Ratio Charts 27
NPS Pharmaceuticals, Inc., Pharmaceuticals and Healthcare, Deals By Year, 2008 to YTD 2014 28
NPS Pharmaceuticals, Inc., Pharmaceuticals and Healthcare, Deals by Type, 2008 to YTD 2014 29

View This Report »

Find all the market research you need - instantly, in one place.

+1.2 Million Research Documents & Statistics +200,000 Trusted Public Sources 350 Industries With Global Coverage

24/7 Customer Support

Talk to Louis

+1 718 618 4302

Purchase Reports From Reputable Market Research Publishers

Recurrent Glioblastoma Multiforme (GBM) - Pipeline Review, H1 2015

Recurrent Glioblastoma Multiforme (GBM) - Pipeline Review, H1 2015

  • $ 2 000
  • Company report
  • March 2015
  • by Global Markets Direct

Recurrent Glioblastoma Multiforme (GBM) - Pipeline Review, H1 2015 Summary Global Markets Direct’s, ‘Recurrent Glioblastoma Multiforme (GBM) - Pipeline Review, H1 2015’, provides an overview of the ...

Pollen Allergy - Pipeline Review, H1 2015

Pollen Allergy - Pipeline Review, H1 2015

  • $ 2 000
  • Company report
  • March 2015
  • by Global Markets Direct

Pollen Allergy - Pipeline Review, H1 2015 Summary Global Markets Direct’s, ‘Pollen Allergy - Pipeline Review, H1 2015’, provides an overview of the Pollen Allergy’s therapeutic pipeline. This report ...

Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) - Pipeline Review, H1 2015

Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) - Pipeline Review, H1 2015

  • $ 2 000
  • Company report
  • February 2015
  • by Global Markets Direct

Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) - Pipeline Review, H1 2015 Summary Global Markets Direct’s, ‘Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) ...

Scar - Pipeline Review, H1 2015

March 2015 $ 2 000

ReportLinker is an award-winning market research solution that finds, filters and organizes the latest industry data so you get all the market research you need - quickly, in one place.